Ozempic and Wegovy are selected for Medicare's price negotiations

Medicare “negotiations” and policy mechanics

• Many note Medicare’s new authority is tightly constrained: only a small, specific list of drugs can be “negotiated,” a compromise shaped by pharma lobbying.
• Several posters argue this isn’t a real negotiation but de facto price setting backed by punitive taxes if manufacturers refuse.
• Others contrast U.S. practice with other countries’ “purchasing controls” (state buyer simply refuses overpriced drugs) rather than hard price caps, and suggest using QALY-style value thresholds.
• Debate over whether such price-setting undermines patent-era monopoly incentives vs. merely correcting monopoly abuses.

Drug pricing, patents, and R&D incentives

• Repeated comparisons: semaglutide is dramatically cheaper in Europe and other markets than in the U.S., despite being the same branded drug.
• Some cite studies claiming very low manufacturing cost; others criticize those analyses as ignoring R&D, labor, QA, and regulatory overhead.
• One camp stresses high prices are needed to recoup multi‑billion‑dollar development costs and failed projects; another claims outsized margins mostly enrich shareholders and intermediaries.
• Cynical takes on why Ozempic/Wegovy (semaglutide) were picked: patents expiring around 2026 vs. longer protection for tirzepatide (Mounjaro/Zepbound), and possible preference for a U.S. company.
• Proposals include “most‑favored nation” pricing or reference to foreign baskets; critics warn this could restrict access in poor countries or create circular downward pricing.

Clinical effects and the CICO debate

• Multiple users report GLP‑1s dramatically reduce “food noise,” cravings, and portion sizes, sometimes changing food preferences rather than enabling binge‑and‑purge behavior.
• Some see them as confirming calories‑in/calories‑out (CICO): they primarily work by lowering intake. Others argue additional metabolic or behavioral effects may matter.
• Ongoing lay debate: CICO as a physical law vs. its (in)practicality as a weight‑loss prescription given metabolic adaptation, mis‑tracking, and constant hunger.

DIY, compounding, and safety

• Compounded and “research peptide” semaglutide is widely discussed: much cheaper, but legality depends on FDA‑declared shortages.
• Significant concern over non‑sterile home mixing and uncertain product quality/dosage; others report using Chinese or Discord‑sourced peptide powders with no evident infections so far.
• Some recommend reputable compounding pharmacies or clinics; others highlight counterfeit risk even in formal supply chains.

U.S. insurance and system dysfunction

• Many accounts of insurers abruptly changing formularies, forcing switches between GLP‑1s, or denying coverage even for diabetes indications.
• Complaints that PBMs and insurers, not just manufacturers, drive U.S. list prices and distort rebates; attempts by manufacturers to cut list prices can allegedly lead to loss of coverage.
• Frustration that job or plan changes can disrupt ongoing therapy; debate over HIPAA and employer visibility into medications.

Ethical, cultural, and societal angles

• Some view widespread Ozempic use as dystopian: outsourcing willpower and ignoring root causes (ultra‑processed food, built environment).
• Others counter that obesity involves addiction‑like biology and hostile food environments; GLP‑1s are likened to nicotine patches or tools like glasses—technology that makes healthy choices feasible.
• Concerns that focusing on drugs may delay reforms of the food system; others argue harm reduction now is worth it even if upstream fixes lag.

Geopolitics tangent

• A side thread speculates about U.S. pressure on Danish Novo Nordisk as leverage over Greenland; other commenters find this coordination theory implausible.